Category: News
Organizational, research, and community announcements. Posts in this category appear automatically on the Latest News page.
-
Honoring the People Who Built the HHT Field—and Those Building What Comes Next | Awards
At every scientific conference, there are moments when we look forward: toward the next question, the next clinical trial, the next discovery that could…
-
RougeTx Launches with HHT as Lead Therapeutic Program
RougeTx, a new biotechnology company focused on vascular disease, has launched with $58 million in Series A financing to advance RTX-001, an investigational treatment…
-
Tectonic Reports Early Safety Data for TX2100: What It Means for HHT Research
The hereditary hemorrhagic telangiectasia (HHT) treatment landscape continues to grow. On September 29, Tectonic Therapeutic announced early clinical results for TX2100, an investigational therapy…
-
FDA Adds Boxed Warning to Ferric Carboxymaltose Following Petition Led by Cure HHT’s Dr. Scott Olitsky
When something in HHT care isn’t working the way it should, speaking up matters. On August 13, 2026, the US Food and Drug Administration…
-
Cure HHT Announces Palmer Family Fund Young Investigator Travel Award Recipients for 16th HHT International Scientific Conference
MONKTON, MD — AUGUST 20, 2026 — Cure HHT is proud to announce the recipients of the Palmer Family Fund for Young Investigator Travel…
-
Vaderis Therapeutics Announces Series B Financing and Initiation of the Global Phase 3 HEROIC Study
Cure HHT is thrilled to share this important milestone from Vaderis Therapeutics: the initiation of the global Phase 3 HEROIC study evaluating engasertib, an…
-
Atavistik Bio Partners with Cure HHT Clinical Trial Network to Advance Development of ATV-1601 for HHT
Cure HHT is proud to partner with Atavistik Bio as it advances ATV-1601, an investigational oral therapy for people with moderate to severe HHT.…
-
Diagonal Therapeutics Announces First Patient Dosed In Phase 1/2 Diamond Clinical Trial Of Diag723 For HHT
Cure HHT is thrilled to share that the first patient has been dosed in Diagonal Therapeutics’ Phase 1/2 DIAMOND clinical trial evaluating DIAG723 for…
-
Cure HHT Canada Launches as Part of a Growing International Commitment to HHT Care, Research, and Advocacy
Newly strengthened organization will work alongside Cure HHT to improve diagnosis, care, and connection for the Canadian HHT community Cure HHT is proud to…
-
Alder Hey Children’s Hospital Achieves Cure HHT Center of Excellence Designation
Newly recognized international treatment center expands access to expert, coordinated care for people living with HHT MONKTON, MD—Cure HHT is proud to announce that…